| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 441.2 | 422.4 | 361.1 |
| Other income | 2.5 | 3.1 | 2.3 |
| Total income | 443.6 | 425.6 | 363.4 |
| Profit before exceptional items & tax | 80.6 | 80.3 | 69.6 |
| Profit before tax | 80.8 | 80.4 | 69.8 |
| Net profit | 60.3 | 60.1 | 52.3 |
| Operating margin | 18.2% | 18.9% | 19.2% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +15.30% |
|---|---|
| Net profit, quarter on quarter | +0.30% |
| Revenue, year on year | +22.20% |
| Operating profit, year on year | +16.00% |
| Operating profit, quarter on quarter | +1.20% |
BSE results filing, NSE: CORONA. Figures extracted from the filing.
Corona Remedies Ltd: key numbers
- Share price
- ₹2,175.00
- Market cap
- ₹13,302 Cr
- Revenue (annual)
- ₹1,403 Cr
- Net profit (annual)
- ₹185.1 Cr
- P/E (TTM)
- 66.8×Sector 48.7×
- Promoter holding
- 69.00%+0.00% QoQ
- FII holding
- 4.21%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Corona Remedies Ltd
All →Corona Remedies Results Update
Corona Remedies released unaudited Q2 and H1 FY27 results highlights via press release. Revenue grew 22% year on year, with EBITDA and PAT also rising.
Corona Remedies Business Update
Corona Remedies received GMP Compliance Certification from Brazil's ANVISA for its OSD and Hormone facilities in Ahmedabad. This validates export eligibility to the Brazilian pharmaceutical market.
Corona Remedies Board Meeting Date
Corona Remedies Limited will hold a board meeting on October 30, 2026. The board will consider unaudited financial results for the quarter and half-year ended September 30, 2026.
Corona Remedies Other Announcement
This filing contains quarterly shareholding pattern disclosures for Corona Remedies Ltd. It provides details on share distribution as required by regulatory compliance norms.
Corona Remedies Credit Rating
CARE Ratings has reaffirmed and upgraded the credit ratings assigned to Corona Remedies Limited's bank facilities, as disclosed in the latest regulatory filing.
Corona Remedies Capital Structure Change
Sepia Investments Limited, Sage Investment Trust, and Anchor Partners sold 2,629,880 equity shares of Corona Remedies Limited. This non-promoter stake sale is disclosed under SEBI SAST regulations.